According to the latest figures, the current death rate from cancer is 7.6 million people per year, with an additional 12.4 million people annually developing various types of the disease. These alarming figures are set to double by 2030. Better patient care and the search for a cure are of major concern for cancer patients and their families, the medical community, national health systems, the pharmaceutical industry, and society as a whole.

Medical images play an increasingly important role in diagnosing and treating cancer patients. In the clinical setting, imaging data enable physicians to better evaluate whether a cancer patient is responding to therapy and to adjust the therapy accordingly. At the research level, medical images are instrumental in the development and the evaluation of new cancer drugs and innovative therapeutic approaches.

MEDIAN Technologies provides advanced medical imaging products and integrated services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development.

• Based on proprietary image processing algorithms, our software products make the analysis and interpretation of medical imaging data more reliable, less reader-dependent, and easier to accomplish.
• Our efficient imaging workflows optimize data sharing among patient care specialists and the various stakeholders involved in clinical trials.
• Our comprehensive services for clinical trial image management and our unique approach to conducting radiological reviews of image data provide the foundation for optimized oncology drug development and represent a significant paradigm shift in how oncology clinical trials are conducted.

Our goal is to transform image interpretation from an objective art to a quantitative science to facilitate better, more reliable outcomes for cancer patients.